Terrence P. Cescon | Hematology Oncology | West Reading, PA

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

Enrollment Status: Recruiting

Publish Date: January 13, 2025

Intervention Type: Other, Biological, Drug

Study Drugs: Trastuzumab Emtansine, Tucatinib

Study Phase: Phase 3

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Enrollment Status: Suspended

Publish Date: February 25, 2025

Intervention Type: Procedure, Drug, Biological, Radiation, Other

Study Drugs: Cisplatin, Nivolumab

Study Phase: Phase 3

Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Other, Biological, Procedure

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 2

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma

Enrollment Status: Suspended

Publish Date: February 25, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Enrollment Status: Suspended

Publish Date: February 25, 2025

Intervention Type: Biological, Drug, Procedure, Radiation

Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel

Study Phase: Phase 2/Phase 3

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Other, Procedure, Biological

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab

Study Phase: Phase 2

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Other, Biological, Procedure

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride

Study Phase: Phase 3

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Procedure, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: February 24, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate

Study Phase: Phase 2

A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: February 24, 2025

Intervention Type: Biological

Study Drugs: Bevacizumab, Ipilimumab

Study Phase: Phase 2

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Enrollment Status: Completed

Publish Date: February 14, 2025

Intervention Type: Drug

Study Phase: Phase 3

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 3

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate

Study Phase: Phase 2

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Radiation, Drug, Other

Study Drugs: Cisplatin, Triapine

Study Phase: Phase 3

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Drug, Procedure, Biological

Study Phase: Phase 2

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate

Study Phase: Phase 3

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Drug, Other

Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib

Study Phase: Phase 2

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Other, Procedure

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)

Enrollment Status: Active_not_recruiting

Publish Date: February 04, 2025

Intervention Type: Drug, Other

Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 2/Phase 3

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Enrollment Status: Active_not_recruiting

Publish Date: January 30, 2025

Intervention Type: Other, Drug, Radiation, Procedure

Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide

Study Phase: Phase 3

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone

Study Phase: Phase 2

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Enrollment Status: Active_not_recruiting

Publish Date: January 28, 2025

Intervention Type: Other, Drug

Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin

Study Phase: Phase 3

A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT)

Enrollment Status: Active_not_recruiting

Publish Date: January 23, 2025

Intervention Type: Radiation, Drug

Study Phase: Phase 3

A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 23, 2025

Intervention Type: Other, Radiation, Drug

Study Drug: Apalutamide

Study Phase: Phase 2

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2025

Intervention Type: Drug, Other, Radiation

Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide

Study Phase: Phase 2/Phase 3

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2025

Intervention Type: Other, Drug, Radiation

Study Drug: Temozolomide

Study Phase: Phase 2

RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

Enrollment Status: Active_not_recruiting

Publish Date: January 17, 2025

Intervention Type: Other, Radiation

Study Phase: Phase 3

A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 16, 2025

Intervention Type: Radiation, Procedure

Study Phase: Phase 2/Phase 3

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification

Enrollment Status: Active_not_recruiting

Publish Date: January 14, 2025

Intervention Type: Device, Biological, Other, Drug

Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab

Study Phase: Phase 2

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin

Enrollment Status: Active_not_recruiting

Publish Date: January 14, 2025

Intervention Type: Other, Biological, Radiation

Study Drugs: Cetuximab, Durvalumab

Study Phase: Phase 2/Phase 3

A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent

Enrollment Status: Completed

Publish Date: January 13, 2025

Intervention Type: Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: January 03, 2025

Intervention Type: Drug, Biological, Procedure, Other, Radiation

Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine

Study Phase: Phase 3

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 27, 2024

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate

Study Phase: Phase 3

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: December 27, 2024

Intervention Type: Other, Procedure, Biological

Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b

Study Phase: Phase 3

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 20, 2024

Intervention Type: Drug

Study Drugs: TAK-700, Bicalutamide

Study Phase: Phase 3

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 19, 2024

Intervention Type: Radiation

Study Phase: Phase 3

Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor

Enrollment Status: Active_not_recruiting

Publish Date: December 13, 2024

Intervention Type: Drug

Study Drugs: Palbociclib, Fulvestrant

Study Phase: Phase 2

Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2024

Intervention Type: Drug, Biological

Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide

Study Phase: Phase 2

A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 29, 2024

Intervention Type: Drug, Radiation

Study Drug: Cisplatin

Study Phase: Phase 2

Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer

Enrollment Status: Terminated

Publish Date: November 29, 2024

Intervention Type: Radiation

Study Phase: Phase 2

Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Enrollment Status: Active_not_recruiting

Publish Date: November 29, 2024

Intervention Type: Other, Drug

Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide

Study Phase: Phase 3

A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases

Enrollment Status: Completed

Publish Date: November 26, 2024

Intervention Type: Radiation, Drug

Study Phase: Phase 3

Dr. Terrence P. Cescon

Overview

Insurance

Locations

Clinical Research

77 Clinical Trials

8 Total Publications

University Of Penn - Medical Group

University Of Penn - Medical Group

Jefferson University Physicians

Areas of Expertise